Xanamem for Alzheimer's Disease
(XanaMIA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are on symptomatic Alzheimer's medications, your dosage must have been stable for 3 months before joining the trial.
Who Is on the Research Team?
Global Program Lead
Principal Investigator
Actinogen Medical Ltd
Are You a Good Fit for This Trial?
This trial is for men and women aged 50 or older with mild to moderate dementia due to Alzheimer's, who have specific biomarkers in their blood. They must have had a brain scan within the last year and show cognitive impairment on tests. Stable medication use for 3 months is required, as well as a partner to attend visits and report on the participant's condition.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 10 mg of Xanamem or placebo once daily for 36 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Xanamem
Find a Clinic Near You
Who Is Running the Clinical Trial?
Actinogen Medical
Lead Sponsor